Research peptide merchants face the highest debanking rate of any e-commerce vertical. Stripe, PayPal, and Square categorically decline the category. Many high-risk processors that accept CBD, firearms, or nutraceuticals still refuse peptides because of FDA and DEA enforcement risk around specific compounds like BPC-157, semaglutide analogues, and certain SARMs.
Why Research Peptide Merchants Face the Highest Debanking Rates
Peptides occupy a regulatory gray area that makes acquiring banks uncomfortable. The products are not explicitly illegal to sell for research purposes, but the FDA has issued warning letters to companies selling BPC-157 and other peptides with implied human-use claims. The DEA has investigated peptide vendors whose marketing crosses the line from research supply to consumer health product.
- FDA enforcement risk on BPC-157, semaglutide analogues, and specific SARMs
- Elevated chargeback rates from custom synthesis timelines and international shipping
- Reputational risk for acquiring banks associated with 'research chemicals'
- Regulatory gray area around RUO labeling that mainstream compliance teams avoid entirely
FDA Enforcement Trends in 2026
The FDA has intensified enforcement around research peptides, particularly BPC-157. In late 2024, the FDA categorized BPC-157 as a bulk drug substance that cannot be compounded under section 503A or 503B. For research suppliers operating under RUO framing, the direct legal impact is limited — but the indirect effect on payment processing has been severe. Processors see the headlines and paint the entire category with the same brush.
"Underwriters do not always distinguish between a compounding pharmacy selling to patients and a research supplier selling to labs. The burden falls on the merchant to demonstrate compliant RUO positioning."
The RUO Compliance Framework
Research Use Only labeling is the compliance framework that makes peptide payment processing possible. Every element of your business must consistently frame products as research reagents, not consumer health products.
- Every product page must display 'For Research Use Only' and 'Not for human consumption'
- Checkout flow must include a terms checkbox confirming research-use purchase intent
- Physical shipping labels must include RUO designations
- No dosage guides, cycle recommendations, injection instructions, or health claims anywhere
- Customer support staff must never provide usage instructions or health advice
Domestic vs Offshore Processing
Most established peptide merchants need both domestic and offshore processing. Domestic acquirers offer lower rates (3.5-5%) and faster settlement but have stricter documentation requirements and lower chargeback tolerance. Offshore acquirers in Cyprus, Malta, Gibraltar, and certain Caribbean jurisdictions have broader risk appetites for research chemicals — rates run 4-7% with slower settlement, but the relationship is more stable against US FDA enforcement shifts.
Required Documentation for Underwriting
- Certificates of Analysis (COAs) from accredited labs for every product — current within 12 months
- Supplier agreements documenting the source of raw materials and synthesis standards
- RUO labeling documentation — screenshots, physical label samples, checkout flow proof
- Business formation documents: articles of incorporation, EIN, business license
- Bank statements (3-6 months) demonstrating cash flow and business activity
- Previous processing statements if available — disclose terminations upfront
MCC Selection Strategy
The Merchant Category Code assigned to your account determines how card networks monitor your transactions. Peptide merchants typically use MCC 5047 (Laboratory/Scientific Supplies), MCC 5122 (Drugs, Drug Proprietaries, and Sundries), or MCC 5999 (Miscellaneous Specialty Retail). Misclassifying your MCC can result in compliance actions, MATCH listing, or termination.
Chargeback Prevention for Peptide Merchants
- Set explicit fulfillment timelines at checkout — custom synthesis plus shipping can take 2-4 weeks
- Ship every order with tracking; orders over $100 get signature confirmation
- Subscribe to Ethoca and Verifi early alert services to resolve disputes before they become chargebacks
- Use billing descriptors that match your brand and include a support phone number
- Implement cold-chain shipping for temperature-sensitive products to prevent degradation claims
Multi-Rail Architecture
No peptide merchant should depend on a single processor. A multi-rail approach distributes risk across offshore card processing (primary), domestic ACH/eCheck (secondary), cryptocurrency acceptance (tertiary), and domestic card processing where available (backup). This architecture ensures a single termination never kills your revenue.
CFPB Options for Debanked Merchants
If your account was closed and you believe the termination was unjustified, you can file a complaint with the Consumer Financial Protection Bureau. The CFPB has taken active interest in debanking since 2024, particularly for businesses operating legally. Filing creates a paper trail and may prompt the institution to review its decision.
How Cybin Enterprises Helps Peptide Merchants
Cybin Enterprises has placed research peptide merchants across BPC-157, TB-500, SARM, and general research chemical catalogs. We know which processors actively underwrite the RUO category, what documentation they require, and how to structure applications for approval. Our consultation is free — call (412) 218-3006 or submit a consultation request to get started.